ArticleACS omega2025
Adsorption of Isoniazid on Aluminum Silicate Tubular Structures.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tubular morphologies were formed using chemical gardens from aluminum salts, aluminum silicate, where the external surface is formed mainly by silicate and the inner surface is mainly aluminum oxide-hydroxide. Several stages are observed during the formation of tubular aluminosilicates using the Schlieren technique. In this work, the adsorption of a bioactive organic compound on the tubular structures formed from aluminum nitrate and sodium silicate was explored, obtaining surprising results. These tubular structures exhibit a notable adsorption capacity for organic compounds and can transport pharmaceutical drugs, such as isoniazid, yielding up to 10% of the solid weight. They could also be used as an excipient in medicines. Molecular modeling studies of this adsorption process corroborated that it is energetically favorable. This material appears to be a promising candidate for the development of novel drug delivery systems for the treatment of tuberculosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.